Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules by unknown
BriefDefinitive Report
Adhesion ofHuman Basophils, Eosinophils, and
Neutrophils to Interleukin 1-activated Human Vascular
Endothelial Cells: Contributions of Endothelial Cell
Adhesion Molecules
By Bruce S . Bochner,* FrancisW . Luscinskas,f
Michael A . Gimbrone, Jr.,# Walter Newman,S Sherry A . Sterbinsky,*
Claudia P. DerseAnthony,* David Klunk,* and Robert P Schleimer"
From the *Division of Clinical Immunology, Johns Hopkins Asthma and Allergy Center,
Baltimore, Maryland 21224; #the Vascular Research Division, Department ofPathology,
Brigham and Woman's Hospital and Harvard Medical School, Boston, Massachusetts 02115,
and SOtsuka America Pharmaceutical, Inc., Rockville, Maryland 20850
Summary
Cytokines such as interleukin 1 (ILl) promote adhesiveness in human umbilical vein endothelial
cells for leukocytes including basophils, eosinophils, and neutrophils, and induce expression of
adherence molecules includingICAM-1 (intercellular adhesion molecule-1), ELAM-1(endothelial-
leukocyte adhesion molecule-1), and VCAM-1 (vascular cell adhesion molecule-1) . In the present
study, blocking monoclonal antibodies (mAb) recognizing ICAM-1, ELAM-1, and VCAM-1
have been used to compare their roles in 11.,l-induced adhesion ofhuman basophils, eosinophils,
and neutrophils. IL-I treatment of endothelial cell monolayers for 4 hours induced a four- to
eight-fold increase in adhesion for each cell type. Treatment of endothelial cells with either
anti-ICAM-1 or anti-ELAM-1 mAb inhibited IIr1-induced adherence of each cell type. In contrast,
treatment with antiVCAM-1 mAb inhibited basophil and eosinophil (but not neutrophil) adhesion,
and was especially effective in blocking eosinophil adhesion. The effects of these mAb were at
least additive. Indirect immunofluorescence and flow cytometry demonstrated expression ofVLA-4cx
(very late activation antigen-4cx, a counter-receptor for VCAM-1) on eosinophils and basophils
but not on neutrophils . These data document distinct roles for ICAM-1, ELAM-1, and VCAM-1
during basophil, eosinophil, and neutrophil adhesion in vitro, and suggest a novel mechanism
for the recruitment of eosinophils and basophils to sites of inflammation in vivo .
Acute allergic reactions in the skin and airways are often
L .1 followed by a more sustained inflammatory reaction (the
so-called late phase response) characterized by the appearance
of eosinophils and basophils, as well as neutrophils and
mononuclear cells (1) . The fact that increased numbers of
eosinophils and basophils appear during these and other mflam-
matory responses suggests that mechanisms exist which facili-
tate their activation and recruitment to extravascular sites.
Results of studies examining in vitro binding ofpurified leu-
kocyte subtypes to culturedhuman vascular endothelial cells
have suggested that endothelium can play an active role in
the recruitment of leukocytes . The cytokines 11-4 and TNF
can stimulate cultured endothelial cells to acquire adhesive
properties for various peripheral blood leukocytes in vitro
(2-5) . During these treatments, changes in adhesiveness are
associated with the induction on endothelial cells of at least
three distinct adhesion molecules : ICAM-1, ELAM-1, and
VCAM-1, identical to inducible cell adhesion molecule-110
(INCAM-110) and the lE7/2G7 protein (6, 7) . BothELAM-1
and ICAM-1 are important ligands in neutrophil adhesion
to activated endothelium (7-10), while VCAM-1 does not
appear to participate (11, 12) . Since the endothelial cell ad-
herence receptors for eosinophils and basophils are unknown,
we used blockingmAb to ICAM-1, ELAM-1, andVCAM-1
to compare their effects on the adhesion of basophils, eo-






[91), ICAM-1 (Hu5/3, IgG1 [10]), andVCAM-1 (2G7, IgG1 [7])
were generated as previously described. In addition, monoclonal
HP2/1, an IgGI antibody recognizing the ct subunit ofthe leuko-
cyte integrin VLA-4 (CD49d) was purchased (AMACInc., West-
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was used as a control antibody (9) . F(ab')2 preparations of the
above antibodies (except HP2/1) were generated using pepsin diges-
tion as described (7, 10), and used in all blocking experiments.
Endothelial Cell Cultures.
￿
Endothelial cells were isolated fol-
lowing collagenase digestion from human umbilical cord veins, and
grown to confluence as previously described (3) . No cell lines were
used after more than three serial passages.
Isolation ofHuman Human Leukocytes.
￿
Human neutrophils andbasophils
were purified from EDTAanticoagulated venous blood of volun-
teers using density gradient centrifugation methods (3, 5) . Human
eosinophils were purified from normal donors or patients with al-
lergic rhinitis or asthma using a discontinuous Percoll gradient
method or an immunomagnetic bead technique (4,13) . Purity and
viability for neutrophils and eosinophils always exceeded 94%, while
basophil purity ranged between 2-10% .
Leukocyte-Endothelial Cell Monolayer Adhesion Assays.
￿
Neutrophil
and eosinophil adherence to endothelial cells was measured using
the "Cr leukocyte collection assay (3, 4) . Basophil adherence assays
were performed as described (5), using the histamine content of
perchloric acid lysates of adherent cells to quantitate basophil
binding.
Adhesion assays were performed as follows : endothelial cells were
preincubated for4hwith or without 5ng/ml (500 U/ml) ofrecom-
binant human IIr1 (generously provided byDr. Steven Gillis, Im-
munex Corp ., Seattle, WA). Endothelial cells were washed, then
incubatedwith or without saturating concentrations of appropriate
F(ay)2 preparations ofmAb in a final volume of 300 pl (45 min,
37°C) . Leukocytes were then added (100 ul, containing 2-4 x
10° basophils, or 2.5 x 105 neutrophils or eosinophils), and al-
lowed to adhere to the monolayers for 10min at 37°C before removal
ofnonadherent cellsby rinsing . No difference was seen if the anti-
bodies were removed or allowed to remain during the adherence
assay (data not shown) .
Percent ofinhibition of IL-1-stimulated adhesion was calculated
according to the following formula : (1 - [(% adherence to IL1
treated endothelium in the presence of mAb - % adherence to
untreated endothelium in the presence ofmAb)/(% adherence to
11,1 treated endothelium in the absence ofmAb - % adherence
to untreated endothelium in the absence of mAb)]) x 100 . In the
absence of IL1, each of themAbhad no significant effect on leuko-
cyte adhesion to endothelial cells (data not shown) . All statistical
analyses to determine differences between groups were performed
using the Student's paired t test .
Indirect Immunofuorescence and Flow Cytometry.
￿
Basophils, .eo-
sinophils, and neutrophils were evaluated for expression ofVCAM-1
andVLA-4a (CD49d)antigenusing indirect immunofluorescence
andflow cytometry (14) . Basophils were specifically labeled by simul-
taneous incubation with FITC-conjugated polyclonal goat anti-
humanIgE (Kirkegaard andPerry Labs, Inc., Gaithersburg, MD)
as described (14) . Leukocytes were washed and resuspended in
R-PE-conjugated F(ab')2 goat anti-mouse IgG (Tago Inc., Burlin-
game, CA); at least 10,000 leukocytes were evaluatedusing a Coulter
EPICS Profile flow cytometer (Coulter Electronics Inc., Hialeah,
FL) . Appropriate gating wasused to eliminate debris ; for basophil
studies, further gating wasdone to restrict analysis to FITC-positive
(IgE-bearing) cells (14) .
Results and Discussion
Previous studies have established that treatment ofhuman
umbilical vein endothelial cells for 4 h with 5 ng/ml (500
U/ml) of 11,1 is optimal for inducing adhesiveness for neu-







Activation ofhuman endothelial cells by IL1 (4 h, 5 ng/ml)
increases adhesion of human basophils (,&; n = 17), eosinophils (p ;
n = 6), and neutrophils (O ; n - 8) . All values (mean t SEM) for
ILI-induced adhesion were significantly greater than for unstimulated ad-
herence (p < 0.05) .
trophils, eosinophils, and basophils (3-5) . As shown in Fig.
1, treatment ofendothelial cells with IIT1 induced a statisti-
cally significant (four- to eight-fold) increase in the adher-
ence of human neutrophils, eosinophils, and basophils.
Using specific mAb, the role of ICAM-1, ELAM-1, and
VCAM-1 during granulocyte adhesion to cytokine-activated
endothelium was determined . As shown in the upper panel
of Fig . 2, F(ab')2 preparations ofmAb to ICAM-1 (Hu5/3)
and ELAM-1 (1118/7) significantly inhibitedadhesion to IL-
1-activated endothelium for all three cell types . In contrast,
antiVCAM-1(2G7) significantly inhibitedadhesion ofeosino-
phils and basophils, but notneutrophils, to cytokine-activated
endothelium . Interestingly, 2G7 was more effective than any
of the other mAb at inhibiting eosinophil adherence, andwas
less effective at inhibiting basophil adhesion . Inhibition by
2G7 was not dueto its ability to directly bind to the eosino-
phil or basophil, since (a) removalof the antibody before per-
forming the adherence assay did not affect the results and
(b) indirect immunofluorescence and flow cytometric anal-
Figure 2.
￿
Effect of F(ab')2 prep-
arations ofanti-ICAM-1 (Hu5/3,
10 Wg/ml), anti-ELAM-1(1118/7,
50 Jig/ml), antiVCAM-1 (2G7,
10,ug/ml) or controlmAb (W6/
32, anti-HLA class I, 50 Wg/ml)
on adherence of basophils ([I;
n = 3-17), eosinophils (® ; n =
3-6), and neutrophils (/ ; n =
4-8) to IIA-treated (4 h, 5 ng/tnl)
umbilical vein endothelial cells .
After cytokine treatment, endo-
thelial cells were incubated with
the indicated antibodies, and in-
hibition of adherence for each cell
type (mean ± SEM) was deter-
mined. For individual antibodies
(upperpanel), values for statistical
significance were determined by
comparison to the W6/32 con-
trol. In the lower panel, values for
statisticalsignificancewere deter
mined by comparing percent inhibition for the combination of two vs .
three blocking antibodies . 'p < 0.05 ; **p < 0.01 .
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ysis consistently failed to detect VCAM-1 expression on any
of the granulocyte subtypes (data not shown) . The,effects
ofcombining both anti-ELAM-1 and anti-ICAM-1 antibodies
were approximately additive for each of these leukocyte types.
However, the addition ofantiVCAM-1 to this antibody com-
bination had a more than additive effect in inhibiting adhe-
sion of eosinophils and basophils (Fig. 2, lowerpane .
SinceVLA4 (CD49d/CD29) has recently been shown to
be a counter-receptor for VCAM-1 (11), we also measured
VLA4 ot expression on granulocytes . Indirect immunofluores-
cence and flow cytometric analyses (Fig. 3) revealed that
basophils and eosinophils expressed VLA-4 cx(CD49d) ; lack
ofexpression by neutrophils confirmed previous reports (11) .
These studies demonstrate that IIT1-induced enhancement
of endothelial cell adhesiveness for eosinophils and basophils,
like neutrophils, occurs in part throughICAM-1 andELAM-1
mediated mechanisms. Although previous studies haveshown
that cytokine treatment of vascular endothelial cells facili-
tates transendothelial migration for neutrophils, an effect also
mediated via ICAM-1 and ELAM-1 (10), it remains to be
determined whether engagement of these endothelial cell adhe-
sion molecules (and perhaps VCAM-1) promotes transendo-
thelial migration for eosinophils or basophils. These obser-
vations also suggest that the coordinate expression ofICAM-1
and ELAM-1 on endothelial cells in vivomay result in recruit-
ment of all types of granulocytes, with the pattern of tissue
infiltration influenced by the relative number of each leuko-
cyte available in the circulation .
In addition, these experiments clearly demonstrate an im-
portant role ofVCAM-1 surface proteins for eosinophil and
basophil (but not neutrophil) adhesion to IL-1-activated en-
dothelium . Indeed, the potent ability of2G7 to block eosin-
ophil adhesion suggests that VCAM-1 is a major ligand for
eosinophil adhesion to activated endothelium . These findings
contrast with a report in which a different mAb recognizing
VCAM-1 (1.4C3) failed to inhibit eosinophil adhesion to
cytokine-activated endothelium (15) . Since mAb 1.40 is
ineffective at blocking T lymphocyte adhesion to VCAM-1
(15), it is likely that this antibody did not inhibit eosinophil
adherence to endothelial cells because it binds to an epitope
on VCAM-1 not involved in adhesion that is distinct from
the epitope recognized bymAb2G7 . Since pretreatment with
a combination of antibodies recognizing ICAM-1, ELAM-1,
and VCAM-1 caused >90% inhibition of eosinophil adhe-
Bochner et al .
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Bssophils Figure 3 .
￿
Expression of the VLA-4
a subunit (CD49d) on human neutro-
phils, eosinophils, and basophils. Leu-
kocytes were purified, thenlabeled with
mAb and analyzed by flow cytometry
as described in Materials andMethods .
Stippled lines represent labeling with
an irrelevant, isotype-matched control
antibody. Results shown are from a
single experiment representative ofthree
separate experiments .
sion to cytokine activated endothelium (Fig. 2), these three
molecules appear to be the major receptors involved in eosin-
ophil adhesion under these conditions . In contrast, pretreat-
ment with the same combination of antibodies resulted in
only60-70% inhibition of basophil and neutrophil adhesion,
suggesting the possible existence of other epitopes and/or
endothelial cell ligands for these cell types . Since the eosino-
phil and basophil, unlike the neutrophil, express VLA4 (Fig.
3), these data also suggest that eosinophils and basophils, like
lymphocytes and monocytes (11), are capable of binding
VCAM-1 via this receptor. Thus, interaction of eosinophils
and basophils with VCAM-1 expressed locally on endothelial
cells may represent a novel mechanism by which the en-
dothelium may directly promote the recruitment of these and
other leukocytes without influencing neutrophil emigration .
This is of particular interest in light of recent studies sug-
gesting that stimuli such as 114 induce expression ofVCAM-1
in the absence of induction ofELAM-1 and ICAM-1 (refer-
ence 16 and our unpublished observations) .
With regard to allergic inflammation, it is interesting to
note that at sites of late phase cutaneous reactions induced
by allergen in atopic subjects, neutrophils represent the pre-
dominant cell type recruited during the initial hours (17) .
This is in marked contrast to the prominent influx of eo-
sinophils, basophils, and mononuclear cells which occurs
6-12 h after antigen challenge (17) . Based on these data, we
hypothesize that the sequential local expression of endothelial
cell adhesion molecules during these inflammatory events
might play an important role in determining the composi-
tion of the cellular infiltrate . That endothelial cell activation
occurs during allergic reactions is suggested by the observa-
tion that IL-1 is released at sites of cutaneous antigen chal-
lenge in atopic but not in nonatopic subjects or at control
sites (17) . In addition, studies using intracutaneous allergen
challenge have shown that expression ofELAM-1, ICAM-1,
andVCAM-1 on endothelial cells occurs within 2 to 8 h (15,
18), and infusion of anti-ICAM-1 antibodies in asthmatic
monkeys reduces airways eosinophilia and airways hyperreac-
tivity (19) . Taken together, these results strongly suggest that
the local expression ofELAM-1, ICAM-1, and VCAM-1 may
contribute to the recruitment of basophils, eosinophils, and
neutrophils during experimental allergic reactions and in
chronic allergic diseases.References
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